Inte:Ligand

Inte:Ligand is an Austrian scientific-software company established in 2003 in Maria Enzersdorf, Lower Austria, and headquartered that same year in Vienna. Its technology is associated primarily with LigandScout, a software platform for computer-aided drug design, structure-based and ligand-based pharmacophore modeling, virtual screening, molecular alignment, compound-library preparation, and related medicinal-chemistry workflows. The company operates at the intersection of cheminformatics, structural bioinformatics, molecular modeling, and pharmaceutical research. Its software is designed to help researchers interpret interactions between small molecules and biological targets, identify or prioritize potential active compounds, and construct computational workflows for drug discovery. The platform supports the creation of three-dimensional pharmacophores, which represent the spatial arrangement of chemical features important for biological activity. It also supports the screening of compound collections, annotation and filtering of libraries, and the editing and design of molecules. Inte:Ligand's product range includes LigandScout Essential, LigandScout Advanced, and LigandScout Expert KNIME Extensions. Essential provides core capabilities for de novo molecule design, pharmacophore generation, three-dimensional molecular alignment, virtual screening, conformer-library generation, compound annotation, filtering, sorting, and pharmacophore or molecule editing. Advanced builds on those capabilities with functions for molecular docking, apo-site pharmacophore modeling, binding-pocket identification, and analysis of molecular-dynamics trajectories. The Expert KNIME Extensions package makes more than 45 Inte:Ligand algorithms available within KNIME-based workflows, allowing researchers to assemble customized computational pipelines. The company's technology has been used or discussed in research involving virtual screening, three-dimensional pharmacophore modeling, hit identification, medicinal-chemistry decision support, activity profiling, docking, fragment-based compound design, protein-protein interactions, drug repurposing, and molecular-dynamics simulation. Reported application areas include the search for myeloperoxidase ligands, HIV reverse-transcriptase inhibitors, antiviral bioactivity profiling, prediction of HIV-protease activity, cytochrome P450 activity prediction, and modeling of activity against Factor Xa. These examples reflect the breadth of computational questions addressed by the platform rather than a claim that Inte:Ligand itself developed or commercialized the resulting medicines. Inte:Ligand received the Lower Austria Innovation Prize in 2007 for the development of LigandScout. By 2017, more than 1,500 literature articles, book chapters, and review articles were reported as being related to the company's software technology. This publication footprint indicates substantial use or discussion of the platform in academic and applied drug-discovery research. Publicly available reference material does not establish the company's ownership structure, revenue, listing status, executive roster, or detailed geographic sales footprint. Inte:Ligand is therefore best characterized as a specialized Austrian business-to-business scientific-software brand serving researchers and organizations involved in pharmaceutical and molecular-design work.

Inte:Ligand was founded in 2003 in Maria Enzersdorf, in the Austrian state of Lower Austria. In the same year, the company established its headquarters on Mariahilferstrasse in Vienna. From its beginning, the business was associated with the development and commercialization of scientific software for computational chemistry and drug-discovery research, with LigandScout becoming its best-known technology platform. LigandScout was developed to support the representation and analysis of ligand-target interactions through three-dimensional pharmacophores. In drug-design research, pharmacophores describe the spatial arrangement of chemical features that may be important for a molecule's biological activity. A computational platform built around these concepts can help researchers compare molecules, identify shared activity patterns, screen libraries, and propose new compounds before undertaking laboratory testing. The platform expanded beyond basic pharmacophore generation. Its documented capabilities include both ligand-based and structure-based three-dimensional pharmacophore modeling, molecular three-dimensional alignment, virtual screening, creation of multiconformational compound libraries, compound-library annotation, filtering and sorting, and advanced pharmacophore and molecule editing. Later or higher-tier functionality included docking, apo-site pharmacophore modeling, pocket finding, and analysis of molecular-dynamics trajectories. These functions positioned the software as a broader computer-aided drug-design environment rather than a single-purpose modeling utility. In 2007, Inte:Ligand received the Lower Austria Innovation Prize for the development of LigandScout. The award marked an early public recognition of the company's technology and its regional innovation credentials. The platform subsequently appeared in a substantial body of scientific literature. Reference material states that, by 2017, more than 1,500 papers, book chapters, and review articles had been published in connection with Inte:Ligand software technology. The reported research areas span virtual screening, three-dimensional pharmacophore modeling, hit identification, medicinal-chemistry decision support, activity profiling, docking, fragment-based compound design, protein-protein interactions, drug repurposing, and molecular-dynamics simulations. Specific examples include computational work concerning new myeloperoxidase ligands, HIV reverse-transcriptase inhibitors, antiviral bioactivity profiling, predictive models for HIV-protease activity, cytochrome P450 activity prediction, and Factor Xa activity simulations. Such uses demonstrate the software's application across target classes and drug-discovery stages, while the available material does not indicate that Inte:Ligand itself was responsible for every scientific discovery made with the tools. The product portfolio described in reference material includes LigandScout Essential, LigandScout Advanced, and LigandScout Expert KNIME Extensions. Essential covers the core modeling, screening, library, and editing functions. Advanced adds docking, binding-pocket and apo-site analysis, and molecular-dynamics support. The KNIME extensions package makes more than 45 Inte:Ligand algorithms available as KNIME components, enabling users to construct reproducible or customized workflows that combine the company's methods with other data-processing steps. Public reference material provides limited information about later corporate developments, ownership, management, financial performance, and international office structure. It does, however, document the company's continued relevance as a provider of specialist software for computational drug design. On the evidence available, Inte:Ligand's history is primarily a technology-development story: an Austrian company founded in 2003, recognized for LigandScout in 2007, and associated with a broad research literature and a progressively expanded software environment for molecular discovery.

• 2017

  More than 1,500 related publications reported

  [1]Inte:Liganden.wikipedia.org

  Reference material reported that more than 1,500 papers, book chapters, and review articles had been published in connection with Inte:Ligand software technology by this point.

• 2007

  Lower Austria Innovation Prize

  [1]Inte:Liganden.wikipedia.org

  The company received the Lower Austria Innovation Prize for the development of LigandScout.

• 2003

  Inte:Ligand is founded

  [1]Inte:Liganden.wikipedia.org

  Inte:Ligand was founded in Maria Enzersdorf, Lower Austria, and established its headquarters on Mariahilferstrasse in Vienna during the same year.

Specialized scientific software for computer-aided drug design, pharmacophore modeling, virtual screening, molecular docking, and customizable cheminformatics workflows.

• Computer-aided drug-design software

  LigandScout Essential

  LigandScout Essential provides core tools for de novo molecule design and for deriving structure-based and ligand-based three-dimensional pharmacophores. It supports molecular three-dimensional alignment, pharmacophore modeling, virtual screening, creation of multiconformational compound libraries, compound-library annotation, filtering and sorting, and advanced pharmacophore and molecule editing. The product is intended to support computational workflows used in hit identification, molecular comparison, and medicinal-chemistry research.

• Advanced molecular-modeling and drug-design software

  LigandScout Advanced

  LigandScout Advanced includes the functionality described for LigandScout Essential and adds capabilities for molecular docking, apo-site pharmacophore modeling, binding-pocket finding, and analysis of molecular-dynamics trajectories. These features extend the platform from pharmacophore and screening work into structure-based design and the interpretation of dynamic molecular simulations.

• Scientific workflow extensions

  LigandScout Expert KNIME Extensions

  LigandScout Expert KNIME Extensions package more than 45 Inte:Ligand scientific algorithms for use within the KNIME analytics and workflow environment. The extensions are intended to help researchers build customized computer-aided drug-design workflows, combining Inte:Ligand methods with data preparation, screening, analysis, and other computational steps in a configurable pipeline.

1. 1Inte:Liganden.wikipedia.org